Nanofat Transfer: Why the Evidence Doesn't Support Surgery for Skin Quality
Nanofat has been marketed harder than almost any procedure in aesthetics. "Stem cell facelift", "regenerative surgery", "your own cells". The language is compelling, and it sells an idea most patients find appealing: that something taken from your own body must be better than anything injected from a syringe.
We looked properly at what nanofat is, what it can and cannot do, and how its published evidence compares with the non-surgical regenerative treatments we use every day.
The conclusion surprised us less than it might surprise you. For skin quality, texture, scarring and the ageing face, the non-surgical evidence is stronger, the durability data is better, and the treatment is repeatable without a single incision.
Here is the reasoning, with the evidence attached.
First, what nanofat actually is
Fat transfer is not one procedure. Fat harvested by liposuction is processed differently depending on the intended job.
Macrofat is intact fat placed deep for structural volume. Microfat is finer parcels for more superficial contour work. Nanofat is something else entirely. The fat is mechanically emulsified between two syringes joined by a connector, then filtered, and that process deliberately destroys the mature fat cells. What remains is the stromal vascular fraction: stromal cells, extracellular matrix fragments and signalling molecules.
If you have had bio-filler with us, you may be looking at that photograph and finding it oddly familiar to the image below of us mixing it together...
You are right. The mechanical principle is identical. Two syringes, one connector, a biological material pushed repeatedly between them until its structure changes and it becomes injectable. We do exactly this when we prepare bio-filler, converting your own blood into a gel.
The engineering is the same. The starting material is not, and neither is what it takes to obtain it.
Bio-filler starts with a blood draw that takes minutes, in a treatment room, with you awake and driving yourself home afterwards. Nanofat starts with liposuction, which means a surgical facility, anaesthesia, a donor site, and a recovery period before anything is injected into your face at all.
That difference in access is the whole argument of this article, and it is worth holding onto as you read the rest.
There is one further fact about nanofat that marketing tends to bury, and it matters more than anything else on this page.
Nanofat contains no living fat cells. It adds no volume whatsoever. It is not a filler, it is not a lift, and it cannot restore facial structure.
It is a biological skin conditioner, injected superficially, intended to influence skin quality. Any clinic implying that nanofat will restore your cheeks, temples or jawline is describing a different procedure altogether.
What the published evidence actually says
We are not dismissing nanofat. It has a real mechanism and real supporting data. But the data has limits that patients are rarely told about.
A 2025 systematic review in Aesthetic Surgery Journal Open Forum pooled twelve studies on nanofat for skin scarring, including five randomised controlled trials, with participant numbers ranging from twelve to forty-eight. The findings:
Short-term improvements in scar appearance, texture and patient satisfaction were consistently reported.
Histology supported a genuine biological effect: increased skin thickness, new vessel formation and collagen deposition.
Safety was good, with only minor complications reported and no serious adverse events.
Two of the higher-quality randomised trials found no sustained significant benefit beyond twelve months.
The overall level of evidence was rated 4, the authors noted that protocols are not standardised, and they called for longer follow-up before firm conclusions can be drawn.
A separate systematic review of facial fat grafting and skin quality found improvements across nine studies and 301 patients, but the outcome measures were so inconsistent that a meta-analysis could not be performed at all.
So the honest summary is this. Nanofat does something, it is safe, the short-term results are real, and the evidence that it lasts is weak.
The four problems nobody mentions in the consultation
1. It requires surgery to treat a skin problem
Nanofat cannot be produced without liposuction. That means a surgical facility, anaesthesia, a donor site with its own bruising and recovery, a scar risk where the fat is harvested, and a surgeon's fee. All of that to address concerns like crepey under-eye skin or dull texture.
2. There is no standardised protocol
Emulsification technique, filter size, injection depth and volume all vary between operators. There is no agreed method, which is precisely why the published studies are so difficult to compare. Your result depends heavily on which surgeon you happen to see.
3. Your result depends on the quality of your own fat
The regenerative activity of nanofat comes from your adipose-derived cells, and the research consistently shows that the function and yield of these cells decline with donor age, and are further affected by smoking, diabetes and metabolic health.
The uncomfortable implication: the patients most motivated to seek regenerative treatment are frequently the patients whose donor cells are least likely to perform well. A synthetic biostimulator does not have this problem. It performs identically regardless of your age or metabolic health, because the stimulus is standardised and the collagen response comes from the treated area itself.
4. It is an event, not a programme
Ageing is a continuous process. Nanofat is a one-off surgical episode with, on current evidence, an uncertain benefit past twelve months. Repeating it means repeating the liposuction. There is no maintenance layer, no adjustment, and no ability to escalate or scale back based on how you respond.
What we do instead, and why the evidence is stronger
Poly-L-lactic acid biostimulators: Sculptra and Julaine
This is where the longevity argument decisively favours the non-surgical route.
Sculptra was assessed in a randomised controlled pivotal trial of 233 patients with a 25-month follow-up phase, and a more recent randomised controlled trial in cheek wrinkles demonstrated significantly higher responder rates than
untreated controls at 7, 9 and 12 months. That is a longer and more robust durability dataset than anything published for nanofat.
Julaine is a newer CE-marked PLLA biostimulator from Nordberg Medical, manufactured to produce highly uniform microspheres with slow, predictable degradation. It works deeper than a skin booster, and is used where structural support and skin density are both required, with effects reported to develop and persist over an 18 to 24 month period.
PLLA does not add a foreign volume that sits and waits to break down. It provokes your fibroblasts to lay down your own collagen, which is exactly the mechanism nanofat is sold on, delivered without theatre, without liposuction, without a donor site, and with substantially better long-term trial data behind it.
Against nanofat: stronger durability evidence, no surgery, fully repeatable, dose-adjustable across a course.
Polynucleotides are purified DNA fragments that stimulate fibroblast activity with antioxidant and anti-inflammatory effects, acting through adenosine A2A receptor pathways.
This is the treatment that competes with nanofat most directly, because it targets nanofat's two flagship indications, periorbital skin quality and atrophic scarring, and it has been tested against placebo.
A prospective randomised study of highly purified polynucleotides versus placebo in moderate to severe acne scars was published in Aesthetic Surgery Journal.
A randomised exploratory study assessed polynucleotides combined with cross-linked hyaluronic acid for nasolabial folds.
Prospective periorbital data using validated FACE-Q patient-reported outcomes showed greatest improvement and satisfaction at three months after two sessions, sustained at six months, with minimal adverse events.
A split-face randomised trial in the periorbital area found polynucleotides comparable to non-crosslinked hyaluronic acid, with both effective and safe.
If the goal is thin, crepey, poor-quality under-eye skin, this is a course of injections with virtually no downtime, delivering the outcome nanofat requires an operating theatre to attempt.
Against nanofat: same target tissue, placebo-controlled data in the same indications, no surgery, easily repeated.
The category with the largest randomised trial base in aesthetic medicine, and the only option that restores volume immediately, predictably and reversibly. Hyaluronidase means an unwanted result or a vascular complication can be actively managed.
Nanofat competes with none of this, because it adds no volume at all.
Against nanofat: not a contest. Different job, and nanofat cannot do it.
Biofiller with the Cellenis system
For patients whose appeal in nanofat is specifically autologous treatment, your own biology and nothing synthetic, Biofiller made from PRP delivers that principle without liposuction. Blood draw, processing, injection, same appointment.
If "I want it to be my own cells" is the driver, this achieves it in forty minutes rather than in an operating theatre.
Against nanofat: the autologous argument for surgery collapses entirely when an autologous non-surgical option exists.
Nanofat's best evidence is in scars, but in practice tethered atrophic scars need the tether released mechanically. Subcision does that work directly. It does it even better when combined with Sculptra. However, Nanofat is frequently used alongside subcision in surgical practice, which raises a fair question about how much of the published benefit belongs to the release rather than the injectate.
We perform subcision as both standalone in-clinic procedure, and also combine it with biostimulation and needling.
Enerpeel MA, BioRePeel, the Sebastian Rose Signature HydroFacial, and prescription and medical-grade skincare from ZO Skin Health, Obagi, Medik8 and Marini SkinSolutions.
This is the layer that a single surgical procedure can never replicate: continuous, daily, evidence-based management of the skin barrier, pigmentation and cell turnover.
Head to head
Volume restoration. Nanofat: none, not possible. Our programme: immediate with hyaluronic acid filler, gradual and structural with PLLA.
Best durability evidence. Nanofat: two high-quality randomised trials showed no sustained benefit past twelve months. Our programme: Sculptra pivotal randomised trial with a 25-month follow-up phase, and PLLA effects reported over 18 to 24 months.
Standardised protocol. Nanofat: no agreed protocol, results vary by operator. Our programme: manufacturer protocols, validated dilutions, reproducible technique.
Depends on your age and metabolic health. Nanofat: yes, donor cell function declines with age. Our programme: no, the stimulus is standardised.
Anaesthetic and surgical facility. Nanofat: required. Our programme: not required.
Donor site, scar risk and downtime. Nanofat: yes. Our programme: no donor site, minimal downtime.
Repeatable. Nanofat: only by repeating liposuction. Our programme: yes, as a planned course with maintenance.
Adjustable if you respond differently. Nanofat: no. Our programme: yes, between every session.
Reversible. Nanofat: no. Our programme: hyaluronic acid filler is reversible with hyaluronidase.
Our honest position
Nanofat has a legitimate place. If you are already undergoing facial surgery and fat is being harvested anyway, using it to address skin quality at the same time is a sensible use of an opportunity that already exists. In selected scar cases it is a reasonable surgical option.
What we do not accept is nanofat as a standalone reason to undergo liposuction and general anaesthesia when the presenting concern is skin quality. On the current published evidence, a structured non-surgical programme delivers comparable or better outcomes in the same indications, with better durability data, no surgical risk, and the ability to adapt the plan as you respond.
We should be equally clear about the limits on our side. No treatment on this page, and no treatment anywhere, returns skin to a previous state. Regenerative injectables improve collagen density, skin quality and support to a degree that varies between individuals. Response is not uniform. Anyone promising you a guaranteed outcome is selling rather than assessing, and that applies to surgical and non-surgical practitioners equally.
We do not perform fat transfer, and we have no commercial interest in talking you out of it. If a surgical route is genuinely the better answer for what you want, we will tell you and help you ask a surgeon the right questions.
Book an assessment
The most common reason patients feel let down by regenerative treatment is not the product. It is that a skin quality treatment was used for a volume problem, or a volume treatment for a laxity problem.
Sebastian Rose Medical Aesthetics is a medically led clinic in Cardiff. Treatments are carried out by GMC or NMC-registered medical professionals holding Level 7 in Aesthetic Medicine, with 24 years of healthcare experience including emergency medicine and over a decade in full-time medical aesthetics.
Your consultation includes a full facial assessment, a realistic discussion of what each option can and cannot achieve for your face specifically, and a staged plan with defined timelines and review points. If a treatment is not worth your money, we will tell you.
Sebastian Rose Medical Aesthetics, 39 Charles Street, Cardiff, CF10 2GB.
References
Al-sabri G, Alavi S, Alkaabi S, Maningky M, Forouzanfar T, Helder M. The effectiveness of nanofat in the management of skin scars: a systematic review. Aesthetic Surgery Journal Open Forum, 2025.
Gal S, Ramirez JI, Maguina P. The effects of facial lipografting on skin quality: a systematic review. Plastic and Reconstructive Surgery, 2019.
Tonnard P, Verpaele A, Peeters G, Hamdi M, Cornelissen M, Declercq H. Nanofat grafting: basic research and clinical applications. Plastic and Reconstructive Surgery, 2013.
Uyulmaz S, Sanchez Macedo N, Rezaeian F, Giovanoli P, Lindenblatt N. Nanofat grafting for scar treatment and skin quality improvement. Aesthetic Surgery Journal, 2018.
Sculptra Aesthetic (injectable poly-L-lactic acid) summary of safety and effectiveness data. US Food and Drug Administration premarket approval documentation.
Fabi S, Hamilton T, LaTowsky B, et al. Effectiveness and safety of Sculptra poly-L-lactic acid injectable implant in the correction of cheek wrinkles. Journal of Drugs in Dermatology, 2024.
Araco A, Araco F. A prospective randomized study of highly purified polynucleotides versus placebo in the treatment of moderate to severe acne scars. Aesthetic Surgery Journal, 2021.
Araco A, Araco F, Raichi M. Clinical efficacy and safety of polynucleotides highly purified technology combined with cross-linked hyaluronic acid for moderate to severe nasolabial folds: a prospective randomized exploratory study. Journal of Cosmetic Dermatology, 2023.
Ziade G, et al. Prospective observational study of polynucleotide injections for periorbital rhytides. Journal of Cosmetic Dermatology, 2026.
Abuyousif HS, Porcello A, Cerrano M, et al. In vitro evaluation and clinical effects of a regenerative complex with non-cross-linked hyaluronic acid and high-molecular-weight polynucleotide for periorbital treatment. Polymers, 2025.eet, Cardiff, CF10 2GB.
